This phenomenon is due to the upregulation of the expression of glutamine transporters or enzymes by oncogenes such as c-MYC, which accelerate the uptake and metabolism rate of glutamine and then drive the TCA and biosynthetic processes [3, 16] (Fig
In the following article, we undertake an analysis of the factors that have led to this pharmaceutical conundrum and evaluate potential solutions to mitigate the shortfall
The peptide enhances glucose uptake in muscle and adipose tissue by promoting translocation of GLUT4 glucose transporters to the cell membrane, similar to insulins mechanism
Chitosan-based nanoparticles as effective drug delivery Systems-A review
10.1016/j.ijcard.2014.07.021 60 LiL.DavieJ
First, it is an endogenous molecule: it circulates in human plasma at a concentration of roughly 200 ng/mL around age 20, declining to about 80 ng/mL by age 60, a fall that has been linked, at least associatively, to the general decline in tissue regenerative capacity with age